Skip to content
Home/Companies/Biotech/ProTgen

ProTgen

Biotech·US·Active·2yr hold
Entry
2024
Hold
2yr
Status
Active

Who owns ProTgen?

ProTgen is currently owned by Boehringer Ingelheim Venture Fund through Boehringer Ingelheim Venture Fund (2010 vintage), since 2024.

Hand-verified · updated 2026-07-03

Boehringer Ingelheim Venture Fund
Investor
Boehringer Ingelheim Venture Fund
Boehringer Ingelheim Venture Fund · 2010 · Evergreen

Key facts

HQUnited States
SectorBiotech
StatusActive

More from Boehringer Ingelheim Venture Fund

Other portfolio companies in the same fund.

Refoxy Pharmaceuticals
Refoxy Pharmaceuticals
Active
BiotechGermany· 2024
SwitchKine
Active
BiotechSwitzerland· 2024
Synthetica Pioneering
Active
BiotechChina· 2024
Aurobac Therapeutics
Aurobac Therapeutics
Active
BiotechFrance· 2023
Glox Therapeutics
Glox Therapeutics
Active
BiotechUK· 2023
Obulytix
Obulytix
Active
BiotechBelgium· 2023

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS
Track ProTgen

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Who could buy ProTgen?

7 strategic and 113financial buyers match this company's sector and geography profile, ranked from verified European deal history.

Find likely buyers

Get the full record on ProTgen.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyers and MOIC on realized deals (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue